The intersection between DNA damage response and cell death pathways

Experimental Oncology

Volumn 34, Issue 3, 2012, Pages 243-254

  Nowsheen, S ^a   Yang, E S ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Balance between cell survival and death; BRCA1; DNA damage and repair; EGFR; GSK3; p53; Poly(ADP ribose) polymerase

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; DNA DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN P53; SIRTUIN;

APOPTOSIS; CARCINOGENESIS; CELL FATE; CELL SURVIVAL; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA REPAIR; ENZYME INHIBITION; HUMAN; MOLECULAR INTERACTION; NEOPLASM; NONHUMAN; REVIEW; TREATMENT RESPONSE;

APOPTOSIS; DNA DAMAGE; DNA REPAIR; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872471930     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Chittenden T, Harrington EA, O'Connor R, et al. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995; 374: 733-6.
2. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35: 495-516.
3. Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006; 10: 51-64.
4. Bartek J, Lukas C, Lukas J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 2004; 5: 792-804.
5. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071-8.
6. Aziz K, Nowsheen S, Georgakilas AG. Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways. Curr Mol Med 2010; 10: 626-39.
7. Aziz K, Nowsheen S, Pantelias G, et al. Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy. Pharmacol Ther 2011; 133: 334-50.
8. Nowsheen S, Whitley AC, Yang ES. Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapy. Curr Mol Med 2012; 12: 788-803.
9. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993; 341: 1251-4.
10. Savill J. Apoptosis in disease. Eur J Clin Invest 1994; 24: 715-23.
11. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5: 231-7.
12. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57.
13. Reed JC, Green DR. Apoptosis: Physiology and Pathology. Cambridge: Cambridge University Press, 2011.
14. Kroemer G, Martin SJ. Caspase-independent cell death. Nat Med 2005; 11: 725-30.
15. Roos WP, Kaina B. DNA damage-induced apoptosis: From specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett 2012 [Epub ahead of print].
16. Zhivotovsky B, Kroemer G. Apoptosis and genomic instability. Nat Rev Mol Cell Biol 2004; 5: 752-62.
17. Fan TJ, Han LH, Cong RS, et al. Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai) 2005; 37: 719-27.
18. Trisciuoglio L, Bianchi ME. Several nuclear events during apoptosis depend on caspase-3 activation but do not constitute a common pathway. PloS One 2009; 4: e6234.
19. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Ann Rev Physiol 1998; 60: 619-42.
20. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-811.
21. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002; 296: 1635-6.
22. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22: 8628-33.
23. Polo SE, Jackson SP. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev 2011; 25: 409-33.
24. Zhou BBS, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433-9.
25. Robertson A, Klungland A, Rognes T, et al. DNA repair in mammalian cells. Cell Mol Life Sci 2009; 66: 981-93.
26. Falck J, Forment JV, Coates J, et al. CDK targeting of NBS1 promotes DNA-end resection, replication restart and homologous recombination. EMBO Rep 2012; 13: 561-8.
27. Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005; 308: 551-4.
28. Uziel T, Lerenthal Y, Moyal L, et al. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003; 22: 5612-21.
29. Flynn RL, Zou L. ATR: a master conductor of cellular responses to DNA replication stress. Trends Biochem Sci 2011; 36: 133-40.
30. Smith J, Tho LM, Xu N, et al. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010; 108: 73-112.
31. Vermeulen K, van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003; 36: 131-49.
32. Bahassi EM, Ovesen JL, Riesenberg AL, et al. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 2008; 27: 3977-85.
33. Stracker TH, Usui T, Petrini JHJ. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst) 2009; 8: 1047-54.
34. Shieh SY, Ahn J, Tamai K, et al. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000; 14: 289-300.
35. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-9.
36. Pabla N, Huang S, Mi QS, et al. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 2008; 283: 6572-83.
37. Stracker TH, Couto SS, Cordon-Cardo C, et al. Chk2 suppresses the oncogenic potential of DNA replication-associated DNA damage. Mol Cell 2008; 31: 21-32.
38. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009; 9: 738-48.
39. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153-66.
40. Bernstein C, Bernstein H, Payne CM, et al. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002; 511: 145-78.
41. Fattah F, Lee EH, Weisensel N, et al. Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells. PLoS Genet 2010; 6: e1000855.
42. Symington LS, Gautier J. Double-strand break end resection and repair pathway choice. Annu Rev Genet 2011; 45: 247-71.
43. Shibata A, Conrad S, Birraux J, et al. Factors determining DNA double-strand break repair pathway choice in G2 phase. EMBO J 2011; 30: 1079-92.
44. Yun MH, Hiom K. CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature 2009; 459: 460-3.
45. Nakamura K, Kogame T, Oshiumi H, et al. Collaborative Action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair. PLoS Genet 2010; 6: e1000828.
46. Ikura T, Ogryzko VV, Grigoriev M, et al. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 2000; 102: 463-73.
47. Yang ES, Wang H, Jiang G, et al. Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PKdependent repair in mice. J Clin Invest 2009; 119: 1124-35.
48. Dai C, Tang Y, Jung SY, et al. Differential effects on p53-mediated cell cycle arrest vs. apoptosis by p90. Proc Natl Acad Sci USA 2011; 108: 18937-42.
49. Jiang J, Yang ES, Jiang G, et al. p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Res 2011; 71: 5546-57.
50. Pauklin S, Kristjuhan A, Maimets T, et al. ARF and ATM/ATR cooperate in p53-mediated apoptosis upon oncogenic stress. Biochem Biophys Res Commun 2005; 334: 386-94.
51. Thangaraju M, Kaufmann SH, Couch FJ. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 2000; 275: 33487-96.
52. Levine AJ. p53, the cellular gatekeeper review for growth and division. Cell 1997; 88: 323-31.
53. Ryan KM, Ernst MK, Rice NR, et al. Role of NF-kB in p53-mediated programmed cell death. Nature 2000; 404: 892-6.
54. Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. Cell 2011; 145: 92-103.
55. Bock FJ, Villunger A. GSK3 TIPping off p53 to unleash PUMA. Mol Cell 2011; 42: 555-6.
56. Yang ES, Xia F. BRCA1 16 years later: DNA damage-induced BRCA1 shuttling. FEBS J 2010; 277: 3079-85.
57. Nowsheen S, Aziz K, Tran PT, et al. Epigenetic inactivation of DNA repair in breast cancer. Cancer Lett 2012 [Epub ahead of print].
58. Zhang J, Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 2005; 3: 531-9.
59. Wang H, Yang ES, Jiang J, et al. DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. Cancer Res 2010; 70: 6258-267.
60. Feng Z, Kachnic L, Zhang J, et al. DNA damage induces p53-dependent BRCA1 nuclear export. J Biol Chem 2004; 279: 28574-84.
61. Fitzgerald LD, Bailey CK, Brandt SJ, et al. BRCA1 accumulates in the nucleus in response to hypoxia and TRAIL and enhances TRAIL-induced apoptosis in breast cancer cells. FEBS J 2007; 274: 5137-46.
62. Gu M, Li H, Shen C, et al. Cloning and characterization of a new BRCA1 variant: A role for BRCT domains in apoptosis. Cancer Lett 2010; 295: 205-13.
63. Martin SA, Ouchi T. BRCA1 phosphorylation regulates caspase-3 activation in UV-induced apoptosis. Cancer Res 2005; 65: 10657-62.
64. Shao N, Chai YL, Shyam E, et al. Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 1996; 13: 1-7.
65. Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999; 97: 575-86.
66. Wang YL, Wang B, Zhang H, et al. BRCA1 involved in regulation of Bcl-2 expression and apoptosis susceptibility to ionizing radiation. Sci China Phys Mech Astron 2011; 54; 916-22.
67. Laulier C, Barascu A, Guirouilh-Barbat J, et al. Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes. Cancer Res 2011; 71: 3590-602.
68. Freneaux P, Stoppa-Lyonnet D, Mouret E, et al. Low expression of bcl-2 in Brca1-associated breast cancers. Br J Cancer 2000; 83: 1318-22.
69. Mandal PK, Blanpain C, Rossi DJ. DNA damage response in adult stem cells: pathways and consequences. Nat Rev Mol Cell Biol 2011; 12: 198-202.
70. Burma S, Chen DJ. Role of DNA PK in the cellular response to DNA double-strand breaks. DNA Repair (Amst) 2004; 3: 909-18.
71. Rybanska I, Ishaq O, Chou J, et al. PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis. Oncogene 2012 [Epub ahead of print].
72. Espejel S, Franco S, Sgura A, et al. Functional interaction between DNA-PKcs and telomerase in telomere length maintenance. EMBO J 2002; 21: 6275-87.
73. Espejel S, Martín M, Klatt P, et al. Shorter telomeres, accelerated ageing and increased lymphoma in DNA-PKcs-deficient mice. EMBO Rep 2004; 5: 503-9.
74. Sawada M, Sun W, Hayes P, et al. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 2003; 5: 320-9.
75. Cohen HY, Lavu S, Bitterman KJ, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004; 13: 627-38.
76. Luo X, Kraus WL. On PAR with PARP: cellular stress signaling through poly (ADP-ribose) and PARP-1. Genes Dev 2012; 26: 417-32.
77. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39: 8-24.
78. Nowsheen S, Bonner JA, LoBuglio AF, et al. Cetuximab augments cytotoxicity with poly (ADP-ribose) polymerase inhibition in head and neck cancer. PloS One 2011; 6: e24148.
79. Yu SW, Andrabi SA, Wang H, et al. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 2006; 103: 18314-9.
80. Andrabi SA, Kim NS, Yu SW, et al. Poly(ADP-ribose)(PAR) polymer is a death signal. Proc Natl Acad Sci USA 2006; 103: 18308-13.
81. Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: "PAR-laying" NAD+ into a nuclear signal. Genes Dev 2005; 19: 1951-67.
82. Kraus WL, Lis JT. PARP goes transcription. Cell 2003; 113: 677-83.
83. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-14.
84. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287-94.
85. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-44.
86. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-51.
87. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-9.
88. Nowsheen S, Bonner JA, Yang ES. The poly(ADP-ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol 2011; 99: 331-8.
89. Yu SW, Wang H, Poitras MF, et al. Mediation of poly (ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002; 297: 259.
90. Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004; 23: 2785-96.
91. Ye K. PARP inhibitor tilts cell death from necrosis to apoptosis in cancer cells. Cancer Biol Ther 2008; 7: 942-4.
92. Derheimer FA, Kastan MB. Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett 2010; 584: 3675-81.
93. Yoshida K, Ozaki T, Furuya K, et al. ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin. Oncogene 2007; 27: 1183-8.
94. Smith GCM, d'Adda di Fagagna F, Lakin ND, et al. Cleavage and inactivation of ATM during apoptosis. Mol Cell Biol 1999; 19: 6076-84.
95. Wang J, Pabla N, Wang C-Y, et al. Caspase-mediated cleavage of ATM during cisplatin-induced tubular cell apoptosis: inactivation of its kinase activity toward p53. Am J Physiol Renal Physiol 2006; 291: F1300-7.
96. Zinkel SS, Hurov KE, Ong C, et al. A role for proapoptotic BID in the DNA-damage response. Cell 2005; 122: 579-91.
97. Kelly GS. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. Altern Med Rev 2010; 15: 313-28.
98. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-91.
99. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell 2006; 126: 257-68.
100. Yuan Z, Zhang X, Sengupta N, et al. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell 2007; 27: 149-62.
101. Vaitiekunaite R, Butkiewicz D, Krzesniak M, et al. Expression and localization of Werner syndrome protein is modulated by SIRT1 and PML. Mech Ageing Dev 2007; 128: 650-61.
102. Uhl M, Csernok A, Aydin S, et al. Role of SIRT1 in homologous recombination. DNA Repair (Amst) 2009; 9: 383-93.
103. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008; 14: 312-23.
104. Chen WY, Wang DH, Yen RWC, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005; 123: 437-48.
105. Kim EJ, Kho JH, Kang MR, et al. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 2007; 28: 277-90.
106. Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 2008; 9: 123-8.
107. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007; 404: 1-13.
108. Giannakou ME, Partridge L. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 2004; 14: 408-12.
109. Yang Y, Hou H, Haller EM, et al. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J 2005; 24: 1021-32.
110. Ahn B-H, Kim H-S, Song S, et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA 2008; 105: 14447-52.
111. Kawahara TLA, Michishita E, Adler AS, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kB-dependent gene expression and organismal life span. Cell 2009; 136: 62-74.
112. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-40.
113. Sarkar S, Mazumdar A, Dash R, et al. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 2010; 9: 592-602.
114. Okamoto K, Okamoto I, Okamoto W, et al. Role of survivin in EGFR inhibitor induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res 2010; 70: 10402-10.
115. Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007; 4: e315.
116. Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 2007; 4: e294.
117. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
118. Allocati N, Di Ilio C, De Laurenzi V. p63/p73 in the control of cell cycle and cell death. Exp Cell Res 2012; 318: 1285-90.
119. Sun Q, Ming L, Thomas SM, et al. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene 2009; 28: 2348-57.
120. Dittmann K, Mayer C, Kehlbach R, Rodemann HP. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer 2008; 7: 69.
121. Bandyopadhyay D, Mandal M, Adam L, et al. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998; 273: 1568-73.
122. Mills CN, Nowsheen S, Bonner JA, et al. Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. Front Mol Neurosci 2011; 4: 47.
123. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006; 79: 173-89.
124. Gotschel F, Kern C, Lang S, et al. Inhibition of GSK3 differentially modulates NF-kB, CREB, AP-1 and B-catenin signaling in hepatocytes, but fails to promote TNF-alpha-induced apoptosis. Exp Cell Res 2008; 314: 1351-66.
125. Charvet C, Wissler M, Brauns-Schubert P, et al. Phosphorylation of Tip60 by GSK-3 determines the induction of PUMA and apoptosis by p53. Mol Cell 2011; 42: 584-96.
126. Watcharasit P, Bijur GN, Song L, et al. Glycogen synthase kinase-3B (GSK3B) binds to and promotes the actions of p53. J Biol Chem 2003; 278: 48872-9.
127. Bijur GN, Jope RS. Opposing actions of phosphatidylinositol 3′kinase and glycogen synthase kinase 3B in the regulation of HSF1 activity. J Neurochem 2000; 75: 2401-8.
128. Yang ES, Nowsheen S, Wang T, et al. Glycogen synthase kinase 3B inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neurons. Neuro-Oncology 2011; 13: 459-70.